TY - JOUR
T1 - Glycemic modulation in neuro-oncology
T2 - Experience and future directions using a modified Atkins diet for high-grade brain tumors
AU - Strowd, Roy E.
AU - Cervenka, Mackenzie C.
AU - Henry, Bobbie J.
AU - Kossoff, Eric H.
AU - Hartman, Adam L.
AU - Blakeley, Jaishri O.
N1 - Publisher Copyright:
© The Author(s) 2015.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Dietary glycemic modulation through high-fat, low-carbohydrate diets, which induce a state of systemic ketosis and alter systemic metabolic signaling, have been incorporated into the clinical management of patients with neurological disease for more than a century. Mounting preclinical evidence supports the antitumor, proapoptotic, and antiangiogenic effects of disrupting glycolytic metabolism through dietary intervention. In recent years, interest in incorporating such novel therapeutic strategies in neuro-oncology has increased. To date, 3 published studies incorporating novel dietary therapies in oncology have been reported, including one phase I study in neuro-oncology, and have set the stage for further study in this field. In this article, we review the biochemical pathways, preclinical data, and early clinical translation of dietary interventions that modulate systemic glycolytic metabolism in the management of primary malignant brain tumors. We introduce the modified Atkins diet (MAD), a novel dietary alternative to the classic ketogenic diet, and discuss the critical issues facing future study.
AB - Dietary glycemic modulation through high-fat, low-carbohydrate diets, which induce a state of systemic ketosis and alter systemic metabolic signaling, have been incorporated into the clinical management of patients with neurological disease for more than a century. Mounting preclinical evidence supports the antitumor, proapoptotic, and antiangiogenic effects of disrupting glycolytic metabolism through dietary intervention. In recent years, interest in incorporating such novel therapeutic strategies in neuro-oncology has increased. To date, 3 published studies incorporating novel dietary therapies in oncology have been reported, including one phase I study in neuro-oncology, and have set the stage for further study in this field. In this article, we review the biochemical pathways, preclinical data, and early clinical translation of dietary interventions that modulate systemic glycolytic metabolism in the management of primary malignant brain tumors. We introduce the modified Atkins diet (MAD), a novel dietary alternative to the classic ketogenic diet, and discuss the critical issues facing future study.
KW - Cancer metabolism
KW - Glioma
KW - Ketogenic diet
KW - Modified Atkins diet
KW - Seizure
UR - http://www.scopus.com/inward/record.url?scp=85015682780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015682780&partnerID=8YFLogxK
U2 - 10.1093/nop/npv010
DO - 10.1093/nop/npv010
M3 - Article
AN - SCOPUS:85015682780
SN - 2054-2577
VL - 2
SP - 127
EP - 136
JO - Neuro-Oncology Practice
JF - Neuro-Oncology Practice
IS - 3
ER -